Cardiovascular Diseases

The research at Centrum Badan Klinicznych Piotr Napora Lekarze sp.p. focuses on atrial fibrillation and its complications, aiming to reduce the incidence of ischemic stroke in patients who cannot use oral anticoagulants. The trials evaluate the safety and effectiveness of novel agents that may offer an alternative to standard therapy.

  • Evaluating a new monoclonal antibody for stroke risk reduction
  • Assessing safety profiles in high‑risk cardiac patients
  • Comparing outcomes with existing anticoagulation strategies

With a total of eight ongoing studies, the site in Wroclaw contributes valuable data to cardiovascular research, involving five dedicated investigators.

Digestive System Diseases

Investigations target conditions such as ulcerative colitis, cholestasis, and hepatic complications of cirrhosis. Trials test oral therapies like NX‑13 and evaluate long‑term safety of linerixibat for cholestatic pruritus, while also exploring rifaximin to delay hepatic encephalopathy‑related hospitalizations.

  • Oral NX‑13 efficacy in moderate to severe ulcerative colitis
  • Long‑term safety of linerixibat for cholestatic itch
  • Rifaximin formulation to prevent encephalopathy decompensation

The centre’s multidisciplinary team is advancing therapeutic options for liver and intestinal diseases, supporting patients across Poland and Europe.

Respiratory Tract Diseases

The site conducts studies on asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. Research includes biologics such as astegolimab to lower COPD exacerbations, add‑on inhaled treatments like CHF6001 to improve asthma control, and long‑term assessment of BI 1291583 in bronchiectasis patients.

  • Astegolimab efficacy in reducing COPD flare‑ups
  • CHF6001 as adjunct therapy for persistent asthma
  • BI 1291583 safety in chronic bronchiectasis
  • Tanimilast evaluation in uncontrolled asthma on background therapy

These respiratory trials enhance understanding of disease management and aim to improve quality of life for individuals with chronic lung conditions.